News Conference News ACC 2025 Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years L.A. McKeown March 30, 2025
News Conference News ACC 2025 More ALIGN-AR Data Bolster Potential for a Dedicated AR Device Yael L. Maxwell March 30, 2025
News Conference News ACC 2023 Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients Todd Neale March 05, 2023
News Conference News ACC 2020 PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients Yael L. Maxwell March 29, 2020
News Conference News ACC 2019 Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery Michael O'Riordan March 17, 2019
News Conference News ACC 2018 Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint Caitlin E. Cox March 19, 2018
News Conference News ACC 2018 NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients Shelley Wood March 10, 2018
News Conference News ACC 2017 SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients Todd Neale March 17, 2017
News Conference News ACC 2016 Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients L.A. McKeown April 04, 2016
News Conference News ACC 2016 Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial Yael L. Maxwell April 03, 2016
News Conference News ACC 2016 TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral Shelley Wood April 02, 2016
News Conference News ACC 2015 Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR Yael L. Maxwell March 15, 2015
News Conference News ACC 2015 Follow-up TAVR Studies Reassure About Valve Durability, Outcomes Todd Neale March 15, 2015
News Conference News ACC 2014 ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation Yael L. Maxwell April 03, 2014
News Conference News ACC 2014 CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks L.A. McKeown March 31, 2014
News Conference News ACC 2014 Melody Valve Post-Approval Study Demonstrates Results Better than Originally Predicted Yael L. Maxwell March 30, 2014
News Conference News ACC 2014 TAVR With the CoreValve Device Superior to Surgery at 1 Year Yael L. Maxwell March 29, 2014
News Conference News ACC 2013 ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting L.A. McKeown March 14, 2013
News Conference News ACC 2013 PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished Yael L. Maxwell March 11, 2013
News Conference News ACC 2013 PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device L.A. McKeown March 09, 2013